Cost-Effectiveness of Neoadjuvant Pembrolizumab plus Chemotherapy Followed by Adjuvant Pembrolizumab in Patients with High-Risk, Early-Stage, Triple-Negative Breast Cancer in Switzerland-Reference-Cited by-同舟云学术

Cost-Effectiveness of Neoadjuvant Pembrolizumab plus Chemotherapy Followed by Adjuvant Pembrolizumab in Patients with High-Risk, Early-Stage, Triple-Negative Breast Cancer in Switzerland

Published:2023-11-24 Issue:1 Volume:8 Page:91-101
ISSN:2509-4262
Container-title:PharmacoEconomics - Open
language:en
Short-container-title:PharmacoEconomics Open

Author:

Favre-Bulle Andrea^ORCID,Huang Min^ORCID,Haiderali Amin,Bhadhuri Arjun^ORCID

Funder

MSD

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Health Policy,Pharmacology

Link

https://link.springer.com/content/pdf/10.1007/s41669-023-00445-8.pdf

Reference51 articles.

1. International Agency for Research on Cancer. Breast [Online]. https://gco.iarc.fr/today/data/factsheets/cancers/20-Breast-fact-sheet.pdf. Accessed 9 Nov 2022.

2. Sung H, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–49. https://doi.org/10.3322/caac.21660. (in Eng).

3. Federal Statistical Office. Swiss Confederation. Swiss cancer report. https://www.swissstats.bfs.admin.ch/collection/ch.admin.bfs.swissstat.de.issue211411772100/article/issue211411772100-02. Accessed 8 June 2023.

4. National Agency for Cancer Registration. Cancer mortality. https://www.nacr.ch/en/statistics-atlas/national-statistics-on-cancer-mortality/. Accessed 8 June 2023.

5. International Agency for Research on Cancer. "Switzerland [Online]." https://gco.iarc.fr/today/data/factsheets/populations/756-switzerland-fact-sheets.pdf. Accessed 9 Nov 2022.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-Utility Analysis of Adjuvant Olaparib for Germline BRCA1/2-Mutated, High-Risk HER2-Negative Early Breast Cancer in Spain;PharmacoEconomics - Open;2024-08-19

2. Evaluating the Validation Process: Embracing Complexity and Transparency in Health Economic Modelling;PharmacoEconomics;2024-03-18